Drug Trial Radar · NCT02444793
A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Feb 27, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
24
Actual
Start
May 2015
Primary completion
Sep 2017
Study completion Oct 2017
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Kyowa Kirin Co., Ltd.
- First posted
- May 14, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase 1b, open label, multi center, multi-dose trial designed to estimate the maximum tolerated dose (MTD) and select the recommended dose for phase 2 (RP2D) investigations of PF- 05082566 in combination with KW-0761 (mogamulizumab) in patients with advanced solid tumors. Once the MTD of PF-05082566 administered in combination with KW-0761 is estimated (dose finding), one or more expansion cohorts of patients with selected advanced solid tumors (dose-expansion ) will be enrolled to further characterize the combination in term of safety profile, anti tumor activity, pharmacokinetics, pharmacodynamics and biomarkers modulation.
Conditions
- Advanced/Metastatic Solid Tumors
Interventions
PF-05082566Drug
Part 1: PF-05082566 dose escalation; Increased doses of PF-05082566 IV are administered at appropriate intervals. Part 2: MTD of PF-05082566 IV established in Part 1 is administered.
KW-0761Drug
Part 1: KW-0761 IV administered at appropriate intervals. Part 2: KW-0761 IV administered at appropriate intervals at the MTD dose for the combination.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose Limiting Toxicities (DLT)Time frame: First 2 Cycles (28 days in each cycle)
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
UC San Diego Moores Cancer Center
La Jolla, California
UC San Diego Medical Center - La Jolla(Thornton Hospital)
La Jolla, California
University Of California / San Diego Moores Cancer Center
La Jolla, California
University of California San Diego Moores Cancer Center
La Jolla, California
UC San Diego Medical Center - Hillcrest
San Diego, California
Georgetown University Medical Center
Washington D.C., District of Columbia
Georgetown University
Washington D.C., District of Columbia
Medstar Georgetown University Hospital
Washington D.C., District of Columbia
Moffitt Cancer Center and Research Institute
Tampa, Florida
Henry Ford Hospital Research Pharmacy
Detroit, Michigan
Henry Ford Hospital
Detroit, Michigan
UNC Cancer Hospital Infusion Pharmacy
Chapel Hill, North Carolina
UNC Hospitals, University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio
Cleveland Clinic
Cleveland, Ohio
Sanford Cancer Center
Sioux Falls, South Dakota
Sanford Research
Sioux Falls, South Dakota
Sanford USD Medical Center
Sioux Falls, South Dakota
Tennessee Oncology, PLLC
Gallatin, Tennessee
Tennessee Oncology, PLLC
Nashville, Tennessee
The Sarah Cannon Research Institute
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.